CA2579303A1 - 2-substituted-1-deaza purine derivatives with adenosine receptor modulating activity - Google Patents
2-substituted-1-deaza purine derivatives with adenosine receptor modulating activity Download PDFInfo
- Publication number
- CA2579303A1 CA2579303A1 CA002579303A CA2579303A CA2579303A1 CA 2579303 A1 CA2579303 A1 CA 2579303A1 CA 002579303 A CA002579303 A CA 002579303A CA 2579303 A CA2579303 A CA 2579303A CA 2579303 A1 CA2579303 A1 CA 2579303A1
- Authority
- CA
- Canada
- Prior art keywords
- amino
- methyl
- deazapurine
- compound
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000009346 Adenosine receptors Human genes 0.000 title abstract description 18
- 108050000203 Adenosine receptors Proteins 0.000 title abstract description 18
- 230000000694 effects Effects 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 62
- 238000000034 method Methods 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- -1 2-oxa-3-azabicyclo[2.2.2]oct-5-en-3-yl Chemical group 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 11
- 150000001412 amines Chemical class 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 4
- 150000002429 hydrazines Chemical class 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010051290 Central nervous system lesion Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000003251 Pruritus Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 208000024780 Urticaria Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 208000005298 acute pain Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 230000006793 arrhythmia Effects 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 208000029028 brain injury Diseases 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 208000015114 central nervous system disease Diseases 0.000 claims description 2
- 208000007451 chronic bronchitis Diseases 0.000 claims description 2
- 230000019771 cognition Effects 0.000 claims description 2
- 230000006735 deficit Effects 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 210000000987 immune system Anatomy 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- 208000017520 skin disease Diseases 0.000 claims description 2
- 201000002859 sleep apnea Diseases 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 231100000397 ulcer Toxicity 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000543 intermediate Substances 0.000 abstract description 21
- 238000003786 synthesis reaction Methods 0.000 abstract description 8
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 abstract description 2
- 150000003212 purines Chemical class 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 78
- 239000000047 product Substances 0.000 description 30
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 23
- 239000007787 solid Substances 0.000 description 21
- 238000005481 NMR spectroscopy Methods 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 16
- 239000000203 mixture Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000000725 suspension Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 238000003818 flash chromatography Methods 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- 101000783645 Homo sapiens Adenosine receptor A3 Proteins 0.000 description 5
- 235000011114 ammonium hydroxide Nutrition 0.000 description 5
- 229940126214 compound 3 Drugs 0.000 description 5
- 102000046278 human ADORA3 Human genes 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000002287 radioligand Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000006396 nitration reaction Methods 0.000 description 4
- 238000001525 receptor binding assay Methods 0.000 description 4
- 238000003260 vortexing Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- RIAJKIRSFJZWEJ-UUOKFMHZSA-N (2r,3r,4s,5r)-2-(6-amino-2-nitrosopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical class C1=NC=2C(N)=NC(N=O)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RIAJKIRSFJZWEJ-UUOKFMHZSA-N 0.000 description 2
- LLNAMUJRIZIXHF-CLFYSBASSA-N (z)-2-methyl-3-phenylprop-2-en-1-ol Chemical compound OCC(/C)=C\C1=CC=CC=C1 LLNAMUJRIZIXHF-CLFYSBASSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 108010060261 Adenosine A3 Receptor Proteins 0.000 description 2
- 102000008161 Adenosine A3 Receptor Human genes 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Substances CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101000783751 Homo sapiens Adenosine receptor A2a Proteins 0.000 description 2
- 101000783756 Homo sapiens Adenosine receptor A2b Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 150000003838 adenosines Chemical class 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 102000055905 human ADORA2A Human genes 0.000 description 2
- 102000055126 human ADORA2B Human genes 0.000 description 2
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- QOWBXWFYRXSBAS-UHFFFAOYSA-N (2,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C(OC)=C1 QOWBXWFYRXSBAS-UHFFFAOYSA-N 0.000 description 1
- LOGOEBMHHXYBID-WBKNRDRNSA-N (2s,3s,4r,5r)-5-[6-[(4-amino-3-iodanylphenyl)methylamino]purin-9-yl]-3,4-dihydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=C([125I])C(N)=CC=3)=C2N=C1 LOGOEBMHHXYBID-WBKNRDRNSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000004293 19F NMR spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- GKNVWOWIFVSUFJ-UHFFFAOYSA-N 7-nitro-1h-imidazo[4,5-b]pyridine Chemical compound [O-][N+](=O)C1=CC=NC2=C1NC=N2 GKNVWOWIFVSUFJ-UHFFFAOYSA-N 0.000 description 1
- FFBDFADSZUINTG-LEZITTIZSA-N 8-cyclopentyl-1,3-bis(1,3-ditritiopropyl)-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(C([3H])CC[3H])C(=O)N(C([3H])CC[3H])C=2N=C1C1CCCC1 FFBDFADSZUINTG-LEZITTIZSA-N 0.000 description 1
- 101150046889 ADORA3 gene Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 238000006596 Alder-ene reaction Methods 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- PAOANWZGLPPROA-RQXXJAGISA-N CGS-21680 Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(NCCC=3C=CC(CCC(O)=O)=CC=3)=NC(N)=C2N=C1 PAOANWZGLPPROA-RQXXJAGISA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 238000005698 Diels-Alder reaction Methods 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- AJBBEYXFRYFVNM-UHFFFAOYSA-N N-(4-cyanophenyl)-2-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)phenoxy]acetamide Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCC(=O)NC1=CC=C(C#N)C=C1 AJBBEYXFRYFVNM-UHFFFAOYSA-N 0.000 description 1
- XTUVJUMINZSXGF-UHFFFAOYSA-N N-methylcyclohexylamine Chemical compound CNC1CCCCC1 XTUVJUMINZSXGF-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Chemical group 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000011949 advanced processing technology Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940010415 calcium hydride Drugs 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cis-cyclohexene Natural products C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- YMWUJEATGCHHMB-DICFDUPASA-N deuterated dichloromethane Substances [2H]C([2H])(Cl)Cl YMWUJEATGCHHMB-DICFDUPASA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- QWLISCJHYITNQF-UHFFFAOYSA-N n-methoxy-1-phenylmethanamine Chemical compound CONCC1=CC=CC=C1 QWLISCJHYITNQF-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 150000002832 nitroso derivatives Chemical class 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000002265 phtalazinyl group Chemical group 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Virology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to 2-substituted-1 -deaza purine derivatives as adenosine receptor modulating agents, to methods for the preparation of these compounds and to novel intermediates useful for the synthesis of sai d purine derivatives. The compounds have the general formula (1) wherein the symbols have the meanings given in the specification.
Description
RECEPTOR MODULATING ACTIVITY
The present invention relates to 2 -substituted -1 -deaza purine derivatives as adenosine receptor modulating agents, to methods for the preparation of these compounds and to novel intermediates useful for the synthesis of said purine derivatives. The invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect. A beneficial effect is disclosed herein or apparent to a person skilled in the art from the specification and general knowledge in the art. The invention also relates to the use of a compound of the invention for the manufacture of a medicament for treating or preventing a disease or condition. More particularly, the invention relates to a new use for the treatment of a disease or condition disclosed herein or apparent to a person skilled in the art from the specification and general knowledge in the art. In embodiments of the invention specific compounds disclosed herein are used for the manufacture of a medicament useful in the treatment of disorders in which adenosine receptors are involved, or that can be treated via manipulation of those receptors.
At present, four types of adenosine receptors have been identified and designated A,, Amõ A2B and A3 respectively. All four belong to the super-family of seven trans-membrane G-protein coupled receptors. Adenosine receptors are ubiquitous and involved in a great variety of biological processes. Thus, duri ng the past decades the therapeutic potential of adenosine receptor ligands has resulted in a substantial research interest.
1-Deaza adenosines are known from EP 0 354 180 A, and were also descri -bed by J.E. Francis et al. (Canadian J. Chem. 70, 1288-1295, 1992) and M.J. Wanner et al.
(Bioorganic & Medicinal Chemistry Letters 2000, 10, 2141 -2144). These compounds were shown to have affinity for adenosine receptors, notably for the adenosine receptor subtype, on which they are agonists. The 1-deaza adenosines described in the documents cited above all contain the 9-p-D-ribofuranosyl substituent characteristic for the natural ligand adenosine. However, highly hydrophilic moieties like ribose have a negative impact on the bioavailability of compounds beari ng such substituents.
The goal of the present invention was to develop 1-deazapurines without a ribose moiety, but with adenosine receptor modulating activity Surprisingly it was found that compounds of the general formula (1):
1-1~ N
\
~
Ri N N
~
(1) R3 wherein - R, represents oxa-3-azabicyclo[2.2.2]oct-5-en-3-yl, 4-hydroxy-cyclohexyl-NH-, optionally substituted arylalkyl(C,_3)amines, cycloalkyl(C3_$)alkyl-(C,_3)amines, arylalkyl(C,_3)hydrazines or cycloalkyl(C3_$)alkyl-(C,_3)hydrazines - R2 represents amino, NH-alkyl(C,_3) or N-dialkyl(C,_3) optionally substituted arylalkyl(C,_3)amines or cycloalkyl(C3_$)alkyl-(C,_3)amines, - R3 represents hydrogen, alkyl(C,_3) or arylalkyl(C,_3) and tautomers, stereoisomers, prodrugs and salts thereof, are new and are adenosine receptor modulators Throughout this specification the generally accepted atom numbering system of the purine skeleton is used:
~
/> $
2kN 4 N
The present invention relates to 2 -substituted -1 -deaza purine derivatives as adenosine receptor modulating agents, to methods for the preparation of these compounds and to novel intermediates useful for the synthesis of said purine derivatives. The invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect. A beneficial effect is disclosed herein or apparent to a person skilled in the art from the specification and general knowledge in the art. The invention also relates to the use of a compound of the invention for the manufacture of a medicament for treating or preventing a disease or condition. More particularly, the invention relates to a new use for the treatment of a disease or condition disclosed herein or apparent to a person skilled in the art from the specification and general knowledge in the art. In embodiments of the invention specific compounds disclosed herein are used for the manufacture of a medicament useful in the treatment of disorders in which adenosine receptors are involved, or that can be treated via manipulation of those receptors.
At present, four types of adenosine receptors have been identified and designated A,, Amõ A2B and A3 respectively. All four belong to the super-family of seven trans-membrane G-protein coupled receptors. Adenosine receptors are ubiquitous and involved in a great variety of biological processes. Thus, duri ng the past decades the therapeutic potential of adenosine receptor ligands has resulted in a substantial research interest.
1-Deaza adenosines are known from EP 0 354 180 A, and were also descri -bed by J.E. Francis et al. (Canadian J. Chem. 70, 1288-1295, 1992) and M.J. Wanner et al.
(Bioorganic & Medicinal Chemistry Letters 2000, 10, 2141 -2144). These compounds were shown to have affinity for adenosine receptors, notably for the adenosine receptor subtype, on which they are agonists. The 1-deaza adenosines described in the documents cited above all contain the 9-p-D-ribofuranosyl substituent characteristic for the natural ligand adenosine. However, highly hydrophilic moieties like ribose have a negative impact on the bioavailability of compounds beari ng such substituents.
The goal of the present invention was to develop 1-deazapurines without a ribose moiety, but with adenosine receptor modulating activity Surprisingly it was found that compounds of the general formula (1):
1-1~ N
\
~
Ri N N
~
(1) R3 wherein - R, represents oxa-3-azabicyclo[2.2.2]oct-5-en-3-yl, 4-hydroxy-cyclohexyl-NH-, optionally substituted arylalkyl(C,_3)amines, cycloalkyl(C3_$)alkyl-(C,_3)amines, arylalkyl(C,_3)hydrazines or cycloalkyl(C3_$)alkyl-(C,_3)hydrazines - R2 represents amino, NH-alkyl(C,_3) or N-dialkyl(C,_3) optionally substituted arylalkyl(C,_3)amines or cycloalkyl(C3_$)alkyl-(C,_3)amines, - R3 represents hydrogen, alkyl(C,_3) or arylalkyl(C,_3) and tautomers, stereoisomers, prodrugs and salts thereof, are new and are adenosine receptor modulators Throughout this specification the generally accepted atom numbering system of the purine skeleton is used:
~
/> $
2kN 4 N
The invention relates to racemates, mixtures of diastereomers as well as the individual stereoisomers of the compounds having formula (1). The invention also relates to the E isomer, Z isomer and E/Z mixtures of compounds having formula (1).
In the description of the substituents the abbreviation 'alkyl(C,_3)' means 'methyl, ethyl, n-propyl or isopropyl'. 'Optionally substituted' means that a group may or may not be further substituted by one or more groups selected from alkyl, alkenyl, alkynyl, aryl, fluoro, chloro, bromo, hydroxyl, alkyloxy, alkenyloxy, aryloxy, acyloxy, amino, alkylamino, dialkylamino, arylamino, thio, alkylthio, arylthio, cyano, oxo, nitro, acyl, amido, alkylamido, dialkylamido, carboxyl, or two optional substituents may together with the carbon atoms to which they are attached form a 5- or 6-membered aromatic or non-aromatic ring containing 0, 1 or 2 heteroatoms selected from nitrogen, oxygen or sulphur. Within the context of the explanation of 'optionally substituted', 'alkyl' means C,_3-alkyl, 'alkenyl' means C,_3-alkenyl, 'alkynyl' means C,_3-alkynyl, 'acyl' means C,_3-acyl and 'aryl' means furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazynyl, phenyl, indazolyl, indolyl, indolizinyl, isoindolyl, benzi[b]furanyl, benzo[b]thiophenyl, benzimidazolyl, benzthiazolyl, purinyl, quinolynyl, isochinolyl, chinolyl, phtalazinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, naphthyl or azulenyl, preferably phenyl, pyridyl of naphthyl.
Optional substituents may themselves bear additional optional substituents. Preferred optional substituents include C,_3 alkyl such as for example methyl, ethyl, and trifluoromethyl, fluoro, chloro, bromo, hydroxyl, C,_3 alkyloxy such as for example methoxy, ethoxy and trifluoromethoxy, and amino.
Prodrugs of the compounds mentioned above are in the scope of the present invention.
Prodrugs are therapeutic agents which are inactive per se but are transformed into one or more active metabolites. Prodrugs are bioreversible derivatives of drug molecules used to overcome some barriers to the utility of the parent drug molecule.
These barriers include, but are not limited to, solubility, permeability, stability, presystemic metabolism and targeting limitations (Medicinal Chemistry:
Principles and Practice, 1994, ISBN 0-85186-494-5, Ed.: F. D. King, p. 215; J. Stella, "Prodrugs as therapeutics", Expert Opin. Ther. Patents, 14(3), 277-280, 2004; P.
Ettmayer et al., "Lessons learned from marketed and investigational prodrugs", J.Med.Chem., 47, 2393-2404, 2004).
Pro-drugs, i.e. compounds which when administered to humans by any known route, are metabolised to compounds having formula (1), belong to the invention. In particular this relates to compounds with primary or secondary amino or hydroxy groups. Such compounds can be reacted with organic acids to yield compounds having formula (1) wherein an additional group is present which is easily removed after administration, for instance, but not limited to amidine, enamine, a Mannich base, a hydroxyl-methylene derivative, an O-(acyloxymethylene carbamate) derivative, carbamate, ester, amide or enaminone.
The invention particularly relates to compounds of the general formula (1) in which :
- R, represents oxa-3-azabicyclo[2.2.2]oct-5-en-3-yl, 4-hydroxy-cyclohexyl-NH-, Ph-CH2-CH=N-NH-, Ph-CH=N-NH-, 4-methoxy-Ph-CH=N-NH-, 2,4-dimethoxy-Ph-CH=N-NH-, cyclohexyl-CH2-N=N- or cyclohexyl-CH=N-NH-, - R2 represents amino and R3 represents methyl and tautomers, stereoisomers and salts thereof.
GENERAL ASPECTS OF SYNTHESES
The synthesis of compounds having formula (I) is outlined in Scheme 1.
Modification and functionalization of the 2-position of the regular (1 -aza)-purine ringsystem has received much attention. Substitution of purine-2-halides with amines proceeds often sluggish and requires high temperatures. The functionalisation of the 2-position in 1-deazapurines is even more difficult because it is a very deactivated system.
An effective alternative is to start with 6-NO2- or 6-Cl-substituted 1-deaza-purines. The synthesis of these starting materials is described by Cristalli et al. (J.
Med. Chem.
1987, 30, 1686-1688) for X = NO2, and by Itoh et al (J. Heterocyclic Chem.
1982, 19, 513-517) for X = Cl.
In the description of the substituents the abbreviation 'alkyl(C,_3)' means 'methyl, ethyl, n-propyl or isopropyl'. 'Optionally substituted' means that a group may or may not be further substituted by one or more groups selected from alkyl, alkenyl, alkynyl, aryl, fluoro, chloro, bromo, hydroxyl, alkyloxy, alkenyloxy, aryloxy, acyloxy, amino, alkylamino, dialkylamino, arylamino, thio, alkylthio, arylthio, cyano, oxo, nitro, acyl, amido, alkylamido, dialkylamido, carboxyl, or two optional substituents may together with the carbon atoms to which they are attached form a 5- or 6-membered aromatic or non-aromatic ring containing 0, 1 or 2 heteroatoms selected from nitrogen, oxygen or sulphur. Within the context of the explanation of 'optionally substituted', 'alkyl' means C,_3-alkyl, 'alkenyl' means C,_3-alkenyl, 'alkynyl' means C,_3-alkynyl, 'acyl' means C,_3-acyl and 'aryl' means furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazynyl, phenyl, indazolyl, indolyl, indolizinyl, isoindolyl, benzi[b]furanyl, benzo[b]thiophenyl, benzimidazolyl, benzthiazolyl, purinyl, quinolynyl, isochinolyl, chinolyl, phtalazinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, naphthyl or azulenyl, preferably phenyl, pyridyl of naphthyl.
Optional substituents may themselves bear additional optional substituents. Preferred optional substituents include C,_3 alkyl such as for example methyl, ethyl, and trifluoromethyl, fluoro, chloro, bromo, hydroxyl, C,_3 alkyloxy such as for example methoxy, ethoxy and trifluoromethoxy, and amino.
Prodrugs of the compounds mentioned above are in the scope of the present invention.
Prodrugs are therapeutic agents which are inactive per se but are transformed into one or more active metabolites. Prodrugs are bioreversible derivatives of drug molecules used to overcome some barriers to the utility of the parent drug molecule.
These barriers include, but are not limited to, solubility, permeability, stability, presystemic metabolism and targeting limitations (Medicinal Chemistry:
Principles and Practice, 1994, ISBN 0-85186-494-5, Ed.: F. D. King, p. 215; J. Stella, "Prodrugs as therapeutics", Expert Opin. Ther. Patents, 14(3), 277-280, 2004; P.
Ettmayer et al., "Lessons learned from marketed and investigational prodrugs", J.Med.Chem., 47, 2393-2404, 2004).
Pro-drugs, i.e. compounds which when administered to humans by any known route, are metabolised to compounds having formula (1), belong to the invention. In particular this relates to compounds with primary or secondary amino or hydroxy groups. Such compounds can be reacted with organic acids to yield compounds having formula (1) wherein an additional group is present which is easily removed after administration, for instance, but not limited to amidine, enamine, a Mannich base, a hydroxyl-methylene derivative, an O-(acyloxymethylene carbamate) derivative, carbamate, ester, amide or enaminone.
The invention particularly relates to compounds of the general formula (1) in which :
- R, represents oxa-3-azabicyclo[2.2.2]oct-5-en-3-yl, 4-hydroxy-cyclohexyl-NH-, Ph-CH2-CH=N-NH-, Ph-CH=N-NH-, 4-methoxy-Ph-CH=N-NH-, 2,4-dimethoxy-Ph-CH=N-NH-, cyclohexyl-CH2-N=N- or cyclohexyl-CH=N-NH-, - R2 represents amino and R3 represents methyl and tautomers, stereoisomers and salts thereof.
GENERAL ASPECTS OF SYNTHESES
The synthesis of compounds having formula (I) is outlined in Scheme 1.
Modification and functionalization of the 2-position of the regular (1 -aza)-purine ringsystem has received much attention. Substitution of purine-2-halides with amines proceeds often sluggish and requires high temperatures. The functionalisation of the 2-position in 1-deazapurines is even more difficult because it is a very deactivated system.
An effective alternative is to start with 6-NO2- or 6-Cl-substituted 1-deaza-purines. The synthesis of these starting materials is described by Cristalli et al. (J.
Med. Chem.
1987, 30, 1686-1688) for X = NO2, and by Itoh et al (J. Heterocyclic Chem.
1982, 19, 513-517) for X = Cl.
X X X
N a N b N c ~~ ~ -- ~
C'N~ N N N 02N N N
I /
/
H Boc Boc X= CI, NOz X N3 Ns ~, N d N e N f OzN~ fN H 02N N N 02N ~ N N
H Rs N>
N g N h O, OzN N N HOHN' N N N N R
N ~ -N
R1 N R1 ~ N N
Scheme 1. (a) BoczO; (b) TBAN/TFAA; (c) MeOH reflux (d) NaN3; (e) substitution (f) Hz/ Pd/C (g) Hz Pd/C. MeOH; (h)NalO4 oxidation; (i) functionalisation of 2-position;
(j) substitution 6-NH2, leading to Rz After BOC-protection selective nitration on the 2-position can be accomplished in an analogous way to the nitration of 9-ribose containing 1-deazapurines published by Deghati, Bieraugel, Wanner and Koomen (Mild and regioselective nitration of 1-deazapurine nucleosides using TBAN/TFAA. Tetrahedron Letters 2000, 41, 569-573). After a subsequent multi -step introduction sequence of a 2-nitroso moiety, the nitroso group can be further modified using Diels -Alder, ene reactions, addition reactions, Mills coupling, and condensation reactions. Additional information about the potential further modifications for analogous 2 -nitrosoadenosines was published by Wanner and Koomen (Synthesis and properties of 2-nitrosoadenosine. Journal of the Chemical Society-Perkin Transactions 1, 2001, 1908-1915).
The selection of the particular synthetic procedures depends on factors known to those skilled in the art such as the compatibility of functional groups with the reagents used, the possibility to use protecting groups, catalysts, activating and coupling reagents and the ultimate structural features present in the final compound being prepared.
Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by mixing a compound of the presen t invention with a suitable acid, for instance an inorganic acid such as hydrochloric acid, or with an organic acid.
The compounds of the invention of the general formula (1), as well as the salts thereof, have adenosine receptor modulating activity. They are useful in the treatment of disorders in which adenosine receptors are involved, or that can be treated via manipulation of those receptors. For instance in: acute and chronic pain, inflammatory diseases including, arthritis, multiple sclerosis, asthma and psoriasis;
gastro-intestinal disorders such as ulcers, inflammatory bowel disease (Crohn's disease) and ulcerative colitis; allergic responses such as eczema, atopic dermatitis and rhinitis; cardio-vascular disorders such as myocardial infarction, arrhythmias, hypertension, thrombosis, anaemia, arteriosclerosis, angina pectoris, cutaneous diseases such as urticaria, lupus erythematosus and pruritus; opthalmological disorders like glaucoma; respiratory disorders including chronic obstructive pulmonary disease, bronchitis and cystic fibrosis; central nervous system disorders including various forms of epilepsy, stroke, depression, sleep apnoea;
disorders characterized by impairment of cognition and memory such as Alzheimer's disease, Creutzfeldt-Jacob disease, Huntington's disease, Parkinson's disease, neurorehabilitation (post-traumatic brain lesions); acute brain or spinal cord injury;
diabetes, osteoporosis, diseases of the immune system, various carcinomas and leukemia, bacterial and viral infections.
PHARMACEUTICAL PREPARATIONS
The compounds of the invention can be brought into forms suitable for administration by means of usual processes using auxiliary substances such as liquid or solid carrier material. The pharmaceutical compositions of the invention may be administered enterally, orally, parenterally (intramuscularly or intravenously), rectally or locally (topically). They can be administered in the form of solutions, powders, tablets, capsules (including microcapsuies), ointments (creams or gel) or suppositories. Suitable excipients for such formulations are the pharmaceutically customary liquid or solid fillers and extenders, solvents, emulsifiers, lubricants, flavorings, colorings and/or buffer substances. Frequently used auxillary substances which may be mentioned are magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars or sugar alcohols, talc, lactoprotein, gelatin, starch, cellulose and its derivatives, animal and vegetable oils such as fish liver oil, sunflower, groundnut or sesame oil, polyethylene glycol and solvents such as, for example, sterile water and mono- or polyhydric alcohols such as glycerol.
Compounds of the present invention are generally administered as pharmaceutical compositions which are important and novel embodiments of the invention because of the presence of the compounds, more particularly specific compounds disclosed herein.Types of pharmaceutical compositions that may be used include but are not limited to tablets, chewable tablets, capsules, sol utions, parenteral solutions, suppositories, suspensions, and other types disclosed herein or apparent to a person skilled in the art from the specification and general knowledge in the art. The invention also includes the preparation or manufacture of sai d pharmaceutical compositions.
In embodiments of the invention, a pharmaceutical pack or kit is provided comprising one or more containers filled with one or more of the ingredients of a pharmaceutical composition of the invention. Associated with such con tainer(s) can be various written materials such as instructions for use, or a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals products, which notice reflects approval by the agency of manufacture, use, or sale for human or veterinary administration.
PHARMACOLOGICAL METHODS
In vitro affinity for human adenosine-A, receptors Affinity of the compounds for human adenosine-A, receptors was determined using the receptor binding assay described by A. Townsend-Nicholson and P.R.
Schofield (Biol. Chem., 269, 2373, 1994), using human recombinant receptors expressed in CHO cells, and [3H]DPCPX as radioligand.
N a N b N c ~~ ~ -- ~
C'N~ N N N 02N N N
I /
/
H Boc Boc X= CI, NOz X N3 Ns ~, N d N e N f OzN~ fN H 02N N N 02N ~ N N
H Rs N>
N g N h O, OzN N N HOHN' N N N N R
N ~ -N
R1 N R1 ~ N N
Scheme 1. (a) BoczO; (b) TBAN/TFAA; (c) MeOH reflux (d) NaN3; (e) substitution (f) Hz/ Pd/C (g) Hz Pd/C. MeOH; (h)NalO4 oxidation; (i) functionalisation of 2-position;
(j) substitution 6-NH2, leading to Rz After BOC-protection selective nitration on the 2-position can be accomplished in an analogous way to the nitration of 9-ribose containing 1-deazapurines published by Deghati, Bieraugel, Wanner and Koomen (Mild and regioselective nitration of 1-deazapurine nucleosides using TBAN/TFAA. Tetrahedron Letters 2000, 41, 569-573). After a subsequent multi -step introduction sequence of a 2-nitroso moiety, the nitroso group can be further modified using Diels -Alder, ene reactions, addition reactions, Mills coupling, and condensation reactions. Additional information about the potential further modifications for analogous 2 -nitrosoadenosines was published by Wanner and Koomen (Synthesis and properties of 2-nitrosoadenosine. Journal of the Chemical Society-Perkin Transactions 1, 2001, 1908-1915).
The selection of the particular synthetic procedures depends on factors known to those skilled in the art such as the compatibility of functional groups with the reagents used, the possibility to use protecting groups, catalysts, activating and coupling reagents and the ultimate structural features present in the final compound being prepared.
Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by mixing a compound of the presen t invention with a suitable acid, for instance an inorganic acid such as hydrochloric acid, or with an organic acid.
The compounds of the invention of the general formula (1), as well as the salts thereof, have adenosine receptor modulating activity. They are useful in the treatment of disorders in which adenosine receptors are involved, or that can be treated via manipulation of those receptors. For instance in: acute and chronic pain, inflammatory diseases including, arthritis, multiple sclerosis, asthma and psoriasis;
gastro-intestinal disorders such as ulcers, inflammatory bowel disease (Crohn's disease) and ulcerative colitis; allergic responses such as eczema, atopic dermatitis and rhinitis; cardio-vascular disorders such as myocardial infarction, arrhythmias, hypertension, thrombosis, anaemia, arteriosclerosis, angina pectoris, cutaneous diseases such as urticaria, lupus erythematosus and pruritus; opthalmological disorders like glaucoma; respiratory disorders including chronic obstructive pulmonary disease, bronchitis and cystic fibrosis; central nervous system disorders including various forms of epilepsy, stroke, depression, sleep apnoea;
disorders characterized by impairment of cognition and memory such as Alzheimer's disease, Creutzfeldt-Jacob disease, Huntington's disease, Parkinson's disease, neurorehabilitation (post-traumatic brain lesions); acute brain or spinal cord injury;
diabetes, osteoporosis, diseases of the immune system, various carcinomas and leukemia, bacterial and viral infections.
PHARMACEUTICAL PREPARATIONS
The compounds of the invention can be brought into forms suitable for administration by means of usual processes using auxiliary substances such as liquid or solid carrier material. The pharmaceutical compositions of the invention may be administered enterally, orally, parenterally (intramuscularly or intravenously), rectally or locally (topically). They can be administered in the form of solutions, powders, tablets, capsules (including microcapsuies), ointments (creams or gel) or suppositories. Suitable excipients for such formulations are the pharmaceutically customary liquid or solid fillers and extenders, solvents, emulsifiers, lubricants, flavorings, colorings and/or buffer substances. Frequently used auxillary substances which may be mentioned are magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars or sugar alcohols, talc, lactoprotein, gelatin, starch, cellulose and its derivatives, animal and vegetable oils such as fish liver oil, sunflower, groundnut or sesame oil, polyethylene glycol and solvents such as, for example, sterile water and mono- or polyhydric alcohols such as glycerol.
Compounds of the present invention are generally administered as pharmaceutical compositions which are important and novel embodiments of the invention because of the presence of the compounds, more particularly specific compounds disclosed herein.Types of pharmaceutical compositions that may be used include but are not limited to tablets, chewable tablets, capsules, sol utions, parenteral solutions, suppositories, suspensions, and other types disclosed herein or apparent to a person skilled in the art from the specification and general knowledge in the art. The invention also includes the preparation or manufacture of sai d pharmaceutical compositions.
In embodiments of the invention, a pharmaceutical pack or kit is provided comprising one or more containers filled with one or more of the ingredients of a pharmaceutical composition of the invention. Associated with such con tainer(s) can be various written materials such as instructions for use, or a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals products, which notice reflects approval by the agency of manufacture, use, or sale for human or veterinary administration.
PHARMACOLOGICAL METHODS
In vitro affinity for human adenosine-A, receptors Affinity of the compounds for human adenosine-A, receptors was determined using the receptor binding assay described by A. Townsend-Nicholson and P.R.
Schofield (Biol. Chem., 269, 2373, 1994), using human recombinant receptors expressed in CHO cells, and [3H]DPCPX as radioligand.
In vitro affinity for human adenosine-A2A receptors Affinity of the compounds for human adenosine-A2A receptors was determined using the receptor binding assay described by D.R. Luthin et al. (Mol.
Pharmacol.,47, 307, 1995), using human recombinant receptors expressed in HEK-293 cells, and [3H]CGS 21680 as radioligand.
In vitro affinity for human adenosine-A2B receptors Affinity of the compounds for human adenosine-A2B receptors was determined using the receptor binding assay described by J.H. Stehle et al. (Mol. Endocrinol., 6, 384, 1992), using human recombinant receptors expressed in HEK-293 cells, and [3H]MRS 1754 as radioligand.
In vitro affinity for human adenosine-A3 receptors Affinity of the compounds for human adenosine-A3 receptors was determined using the receptor binding assay described by C.A. Salvatore et al.: "Molecular cloning and characterization of the human A3 adenosine receptor", Proc. Natl. Acad. Sci.
USA, 90, 10365-10369, 1993. Briefly, membrane preparations were obtained from human recombinant (HEK 293) cells in which the human adenosine-A3 receptor was stably expressed. Membranes were incubated at 22 C for 90 minutes with [1251]-AB-MECA
in the absence or presence of testcompounds in a concentration range from 10 M
down to 0.1 nM, diluted in a suitable buffer. Separation of bound radioactivity from free was done by filtration through Packard GF/B glass fiber filters with several washings with ice-cold buffer using a Packard cell harvester. Bound radioactivity was measured with a scintillation counter (Topcount, Packard) using a liquid scintillation cocktail (Microscint 0, Packard). Measured radioactivity was plotted against the concentration of the displacing test compound and displacement curves were calculated by four-parameter logistic regression, resulting in IC50 values, i.e. that concentration of displacing compound by which 50% of the radioligand is displaced.
Affinity pK, values were calculated by correcting the IC50 values for radioligand concentration and its affinity for the human adenosine-A3 receptor according to the Cheng-Prusoff equation:
pK, = -log (IC50 / (1 + S/Kd) ) in which the IC50 is as described above, S is the concentration [1251]-AB-MECA
used in the assay expressed in mol/I (typically 0.1 nM), and Kd is the equilibrium dissociation constant of [125I]-AB-MECA for human adenosine-A3 receptor s(0.22 nM).
The compounds of the invention have affinity for at least one of the adenosine receptors in one of the binding assays described above. These properties make them useful in the treatment of disorders in which adenosine receptors are involved, or that can be treated via manipulation of these receptors.
According to the procedures described above the compounds of the invention can be prepared. The examples are intended to further illustrate the invention in more detail, and therefore are not deemed to restrict the scope of the invention in any way.
DOSE
The affinity of the compounds of the invention for adenosine A3 receptors was determined as described above. From the binding affinity measured for a given compound of formula (1), one can estimate a theoretical lowest effective dose.
At a concentration of the compound equal to twice the measured Ki-value, nearly 100% of the adenosine A3 receptors likely will be occupied by the compound. Converting that concentration to mg of compound per kg of patient yields a theoretical lowest effective dose, assuming ideal bioavailability. Pharmacokinetic, pharmacodynamic, and other considerations may alter the dose actually administered to a higher or lower value. The dosage expediently administered is 0.001 - 1000 mg/kg, preferably 0.1-100 mg/kg of patient's bodyweight.
TREATMENT
The term "treatment" as used herein refers to any treatment of a human condition or disease and includes: (1) preventing the disease or condition from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it, (2) inhibiting the disease or condition, i.e., arresting its development, (3) relieving the disease or condition, i.e., causing regression of the condition, or (4) relieving the conditions caused by the disease, i.e., stopping the symptoms of the disease.
Pharmacol.,47, 307, 1995), using human recombinant receptors expressed in HEK-293 cells, and [3H]CGS 21680 as radioligand.
In vitro affinity for human adenosine-A2B receptors Affinity of the compounds for human adenosine-A2B receptors was determined using the receptor binding assay described by J.H. Stehle et al. (Mol. Endocrinol., 6, 384, 1992), using human recombinant receptors expressed in HEK-293 cells, and [3H]MRS 1754 as radioligand.
In vitro affinity for human adenosine-A3 receptors Affinity of the compounds for human adenosine-A3 receptors was determined using the receptor binding assay described by C.A. Salvatore et al.: "Molecular cloning and characterization of the human A3 adenosine receptor", Proc. Natl. Acad. Sci.
USA, 90, 10365-10369, 1993. Briefly, membrane preparations were obtained from human recombinant (HEK 293) cells in which the human adenosine-A3 receptor was stably expressed. Membranes were incubated at 22 C for 90 minutes with [1251]-AB-MECA
in the absence or presence of testcompounds in a concentration range from 10 M
down to 0.1 nM, diluted in a suitable buffer. Separation of bound radioactivity from free was done by filtration through Packard GF/B glass fiber filters with several washings with ice-cold buffer using a Packard cell harvester. Bound radioactivity was measured with a scintillation counter (Topcount, Packard) using a liquid scintillation cocktail (Microscint 0, Packard). Measured radioactivity was plotted against the concentration of the displacing test compound and displacement curves were calculated by four-parameter logistic regression, resulting in IC50 values, i.e. that concentration of displacing compound by which 50% of the radioligand is displaced.
Affinity pK, values were calculated by correcting the IC50 values for radioligand concentration and its affinity for the human adenosine-A3 receptor according to the Cheng-Prusoff equation:
pK, = -log (IC50 / (1 + S/Kd) ) in which the IC50 is as described above, S is the concentration [1251]-AB-MECA
used in the assay expressed in mol/I (typically 0.1 nM), and Kd is the equilibrium dissociation constant of [125I]-AB-MECA for human adenosine-A3 receptor s(0.22 nM).
The compounds of the invention have affinity for at least one of the adenosine receptors in one of the binding assays described above. These properties make them useful in the treatment of disorders in which adenosine receptors are involved, or that can be treated via manipulation of these receptors.
According to the procedures described above the compounds of the invention can be prepared. The examples are intended to further illustrate the invention in more detail, and therefore are not deemed to restrict the scope of the invention in any way.
DOSE
The affinity of the compounds of the invention for adenosine A3 receptors was determined as described above. From the binding affinity measured for a given compound of formula (1), one can estimate a theoretical lowest effective dose.
At a concentration of the compound equal to twice the measured Ki-value, nearly 100% of the adenosine A3 receptors likely will be occupied by the compound. Converting that concentration to mg of compound per kg of patient yields a theoretical lowest effective dose, assuming ideal bioavailability. Pharmacokinetic, pharmacodynamic, and other considerations may alter the dose actually administered to a higher or lower value. The dosage expediently administered is 0.001 - 1000 mg/kg, preferably 0.1-100 mg/kg of patient's bodyweight.
TREATMENT
The term "treatment" as used herein refers to any treatment of a human condition or disease and includes: (1) preventing the disease or condition from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it, (2) inhibiting the disease or condition, i.e., arresting its development, (3) relieving the disease or condition, i.e., causing regression of the condition, or (4) relieving the conditions caused by the disease, i.e., stopping the symptoms of the disease.
EXAMPLES
EXAMPLE 1: MATERIALS AND METHODS
All reactions involving moisture sensitive compounds were carried out under a dry nitrogen atmosphere. Dichloromethane (phosphorous pentoxide and calciumhydride), tetrahydrofuran (sodium/benzophenone ketyl) and light petroleum (60-80) were distilled freshly prior to use. All other commercially available chemicals were used without further purification. Reactions were monitored by using thi n-layer chromatography (TLC) on silica coated plastic sheets (Merck silica gel 60 F254) with the indicated eluent. The compounds were visualised by UV light (254 nm) or I2.
Flash chromatography refers to purification using the indicated eluent and Acros silica gel (0.030-0.075 mm). Nuclear magnetic resonance spectra (1H NMR and NMR, APT) were determined in the indicated solvent using a Bruker ARX 400 (1H:
400 MHz, 13C: 100 MHz) at 300 K, unless indicated otherwise. 19F NMR and 13C
NMR experiments were carried out on a Varian Inova 500 spectrometer operating at 11.74 T (499.9 MHz for'H; 125.7 MHz for13C; 50.7 Mhz, 470.4 MHz for 19F) using a 5 mm SW probe. The spectra were determined in deuterated chloroform or dichloromethane obtained from Cambridge Isotope Laboratories Ltd. Chemical shifts (b) are given in ppm downfield from tetramethylsilane (1 H, 13C) or CCI3F
(19F).
Coupling constants J are given in Hz. Peakshapes in the NMR spectra are indicated with the symbols 'q' (quartet), 'dq' (double quartet), 't' (triplet), 'dt' (double triplet), 'd' (doublet), 'dd' (double doublet), 's' (singlet), 'bs' (broad singlet) and 'm' (multiplet).
NH and OH signals were identified after mixing the sample with a drop of D 20.
Melting points were measured with a Buchi B-545 Melting Point apparatus. Mass spectra and accurate mass measurements were performed using a JEOL JMS -SX/SX 102 A Tandem Mass Spectrometer using Fast Atom Bombardement (FAB). A
resolving power of 10,000 (10% valley definition) for high resolution FAB mass spectrometry was used. Extinction coefficients were determined with a HP 8453 UV -Vis spectrophotometer. Analytical HPLC was performed on a C18 column (Inertsil ODS-3, particle size 3 mm; 4.6mm 50mm) using the following elution gradient:
linear gradient of 5 % to 95 % aqueous CH3CN containing 0.04 % HCO2H over 5 min, then 95 % aqueous CH3CN containing 0.04 % HCO2H for 2 min at 2.0 ml min"'. Products were detected at k = 254 nm.
EXAMPLE 2: SYNTHESES OF INTERMEDIATES
Intermediate A: 6-Chloro-9-Boc-l-deazapurine To a solution of 6-chloro-1-deazapurine (10 g, 65.1 mmol, J. Heterocyclic Chem.
1982, 19, 513-517) and BOC2O (19.8 g, 91.2 mmol) in dry dichloromethane (100 ml) was added dimethylaminopyridine (0.5 g, 5 mass%) and the mixture was stirred at room temperature for 30 minutes. The reaction was quenched by adding silica and the mixture was filtered over hyflo. Evaporating the solvent yielded the crude product.
Trituration with petroleum ether followed by treatment with ether yielded the product as a white solid (6.29 g, 76%), mp: 183.5 C decomposition 'H NMR (d 6-DMSO) b 8.89 (s, 1 H, H-8), 8.47-8.46 (d, J 5.3 , 1 H, H-2), 7.62-7.61 (1 H, d, J 5.3, H-1), 1.66 ( s, 9H t-Bu).
Intermediate B: 2-nitro-6-chloro-9-Boc-l-deazapurine A solution of 6-chloro-9-Boc-1-deazapurine (1 g, 3.94 mmol, intermediate A) and tetrabutyl-ammoniumnitrate (1.8 g, 5.91 mmol) in dry dichloromethane (12 ml) was stirred in an ice bath. TFAA (835 L, 5.91 mmol) was added dropwise. After 1.5 h the reaction was complete and MeOH (20 ml) was added.The mixture was concentrated and cooled to give yellow crystals. The crude product was washed with 3x3 ml cold MeOH. Drying in vacuo at 50 C afforded the product (0.916 g, 78%) as yellow needles. mp: 288.2-290 C decomposition 'H NMR (d6-DMSO) b 9.22 (s, 1H, H-8), 8.58 (s, 1H, H-1), 1.68 (s, 9H, t-Bu).
Intermediate C: 2-nitro-6-chloro-l-deazapurine 2-nitro-6-chloro-9-Boc-1-deazapurine (1.0 g, 3.35 mmol, intermediate B) in MeOH
(20 ml) was stirred at 70 C. After 2 h the product started to precipitate.
After 15 h the suspension was cooled at 0 C for 30 min and filtered. The precipitate was washed with cold MeOH and dried in vacuo at 50 C to furnish the product (0.5 g, 76%) as a yellow solid. mp: 294.5 C
'H NMR(ds-DMSO) b 14.20 (bs, 1 H, H-9), 8.92 (s, 1 H, H-8), 8.41 (d, 1 H, H-1).
Intermediate D: 6-nitro-9-Boc-l-deazapurine To a solution of 6-nitro-1-deazapurine (5 g, 30 mmol, J.Med.Chem., 1987, 30, 1688) and BOC2O (10 g, 46 mmol) in dry dichloromethane (100 ml) was added dimethylaminopyridine (0.250 g, 5 mass%) and the mixture was stirred at room temperature for 1.5 h. The reaction was diluted with PE and quenc hed by adding silica and the mixture was filtered over hyflo. Evaporating the solvent yielded the crude product. Crystallization with EA/PE afforded the product (2.28 g, 72 %) as light yellow needles. mp: 223-226 C
'H NMR (d6-DMSO) b 9.11 (s, 1 H, H-8), 8.81 (d, J 5.3 , 1 H, H-2), 8.10 (d J
5.3, 1 H, H-1), 1.67 ( s, 9H t-Bu).
Intermediate E: 2,6-dinitro-l-deazapurine A solution of 6-nitro-9-Boc-1-deazapurine (4 g, 15 mmol, intermediate D) and tetrabutylammoniumnitrate (0.92 g, 23 mmol) in dry dichloromethane (5 ml) was stirred at -18 C. TFAA (430 L, 18 mmol) was added dropwise. After 1.5 h the nitration reaction was complete and MeOH (20 ml) was added.The solution was refluxed for 15h while the product precipitates. Cooling and filtering and drying the suspension furnished the pure product (2.28g, 72%) as light yellow crystals.
mp:
'H NMR (d6-DMSO) b 14.45(bs, 1H, H-9), 9.16(s, 1H, H-8), 8.81 (d, 1H, H-1).
Intermediate F: 2-nitro-6-azido-l-deazapurine First possible route: a suspension of 2-nitro-6-chloro-1-deazapurine (12 mmol, intermediate C) and NaN3 (2.5 g, 37 mmol) in dry DMF (25 ml) was stirred and warmed to 60 C. After 60 h the reaction was cooled to room temperature and water was added slowly (100 ml). The product precipitated and was filtered. Washing with water and ether, followed by drying in vacuo at 50 C furnished the product (2.12g, 82%) as a solid.
Alternative route: a suspension of 2,6-dinitro-1-deazapurine (2.5 g, 12 mmol, intermediate E) and NaN3 (2.4 g, 37 mmol) in dry DMF (20 ml) was stirred at room temperature for 3h. After completion, water was added slowly (100 ml). The product precipitated and was filtered. Washing with water and ether, followed by drying in vacuo at 50 C furnished the product (2.22g, 90%) as a off white solid. mp: 220-C decomposition 'H NMR(d6-DMSO) b 14.02 (bs, 1 H, H-9), 8.78 (s, 1 H, H-8), 7.81 (s, 1 H, 1-H).
Intermediate G: 2-nitro-6-azido-9-methyl-l-deazapurine To a suspension of 2-nitro-6-azido-1-deazapurine (6 g, 29.2 mmol, Intermediate F) and K2CO3 (8.09 g, 58.5 mmol) in dry DMF (150 ml) was added Mel (3.65 ml, 58.5 mmol). After 1 h the reaction was complete and water (300 ml) was added slowly.
The product precipitated and the suspension was cooled in an ice -bath. The crude product was washed with water and ether and dried in vacuo at 50 C to yield 5.61g (88%) of the desired product as a white solid. mp: 171.7 C decomposition 'H NMR (d6-DMSO) b 8.77 (s, 1H H-8), 7.80 (s, 1H, H-1), 3.92 (s, 3H, CH3).
Intermediate H: 2-nitro-6-amino-9-Me-l-deazapurine To a solution of 2-nitro-6-azido-9-methyl-1-deazapurine (1 g, 4.5 mmol, Intermediate G) was added Pd/C 10 % (0.200 g, 20 mol%). The solution was stirred at room temperature under a H2 atmosphere. After 1 h the reaction was complete. Flash chromatography (EA) of the crude reaction mixture afforded the pure product as a red solid (0.775 g. 88 %). mp: 260 - 264 C
'H NMR (d6-DMSO) b 8.35 (s, 1H H-8), 7.36 (s, 1H, H-1), 7.15 (bs, 2H, NH2), 3.79 (s, 3H, CH3).
Intermediate I: 2-hydroxylamino-6-amino-9-methyl-l-deazapurine A suspension of 2-nitro-6-azido-9-methyl-1-deazapurine (1 g, 45.6 mmol, Intermediate H) and 10% Pt/C (0.2 g, 20% m) in EA (200 ml) was refluxed under a H2 athmosphere. After 18h the reaction was filtered over Hyflo (EA/MeOH). The filtrate was used immediately for the oxidation reaction to the nitroso derivative.
'H NMR (d6-DMSO) b 8.34 (s, 1H, H-8), 7.36 (s, 1H, H-1), 7.14 (bs, 2H, NH2), 3.80 (s, 3H, CH3).
Intermediate J: 2-nitroso-6-amino-9-methyl-l-deazapurine The crude mixture of 2-hydroxylamino-6-amino-9-methyl-1 -deazapurine (intermediate I) was cooled to 0 C. An ice-cold solution of Na104 (1.95 g, 9.13 mmol) in H20 (50 ml) was added slowly. After 1h the reaction was complete and the organic layer was separated from the water layer. The aqueous layer was extracted with EA + 5%
MeOH and dried with Na2SO4. The yellow solution was concentrated and triturated with cold MeOH to yield 0.53 g (65%) of the desired product as a red solid.
mp:
220 C.
'H NMR (d6-DMSO) b 8.46 (s,1H, H-8), 7.37 (s,1H, H-1), 7.00 (bs, 2H, NH2), 3.92 (s, 3H, CH3) EXAMPLE 3: SYNTHESES OF SPECIFIC COMPOUNDS
Compound 1: 2-(2-oxa-3-azabicyclo[2.2.2]oct-5-en-3-yl)-6,amino-9-methyl-1-deazapuri ne To a suspension of 2-nitroso-6-amino-9-methyl-1-deazapurine (0.1 g, 0.56 mmol, intermediate J) in MeOH (15 ml) was added slowly 1,3-cyclohexadiene (105 l , 1.13 mmol). After 30 m the reaction was complete and the mixture was concentrated and triturated in cold MeOH. The product was washed with cold MeOH and dried at 50 C
in vacuo to yield 101.9 mg (75 %) of the desired product as a white solid. mp:
169.9 C.
'H NMR (d6-DMSO) b 7.82 (s, 1H, H-8), 6.52 (t, 1H, CH), 6.30 (t, 1H, CH) , 6.12 (bs, 2H, NH2), 5.99 (s, 1 H, H-1), 5.21 (t, 1 H, CH), 4.70 (t, 1 H, CH), 3.63 (s, 3H, CH 3), 2.08 (q, 2H, CH2), 1.55 (q, 2H, CH2), 1.33 (q, 2H, CH2);
m/z 258.1355 (M+ + H. C13H16N50 requires m/z 258.1277) Compound 2: 2-(cis-4-hydroxycyclohexylamino)-6-amino-9-methyl-1-deazapurine A suspension of 2-(2-oxa-3-azabicyclo[2.2.2]oct-5-en-3-yl)-6-amino-9-methyl-1-deazapurine (50 mg, 0.194 mmol, compound 1) and 10% Pd/C in MeOH (4 ml) was stirred under 1 atm hydrogen for 1.5 h at 70 C. Filtration, evaporation and stirring in cold MeOH afforded the pure 2-(cis-4-hydroxycyclohexylamino)-6-amino-9-methyl-deazapurine (23,8 mg, 47 %) as white solid.
'H NMR (d6-DMSO) b 7.62 (s, 1H, 8-H), 5.72 (s, 2H, NH2), 5.69-5.67 (m, 1H, NH), 5.57 (s, 1 h, 1-H), 4.34 (s, 1 H, OH), 3.69 (s, 2H), 3.57 (s, 3H, CH 3), 1.63 (m, 6H, cyclo), 1.53-151 (m, 2H, cyclo) m/z 262.1668 (M+ + H. C13H19N50 requires m/z 262.1590) Compound 3:2-(2-phenylethyl-hydrazone)-6-amino-9-methyl-1-deazapurine A mixture of 2-nitroso-6-amino-9-methyl-1-deazapurine (0.1 g, 0.565 mmol), 2-phenylethylamine (858 l, 0.677 mmol) and acetic acid CH3COOH (64.6 l, 1.13 mmol) was stirred in MeOH. After 3 h the suspension had dissolved. The yellow solution was concentrated and diluted with PE and purified by flash chromatography (EA/MeOH/NH4OH 88.5:10:1.5). The product was triturated with cold methanol and dried in vacuo to yield 55.4 mg (35%) of the desired product as a yellow solid. mp:
182.1 C
'H NMR (d6-DMSO) b 10.07 (s, 1H, NH), 7.73 (s, 1H, 8-H), 7.37-7.32 (3H, m, CH/Ph), 7.27-7.25-7.23 (m, 3H, Ph), 6.28 (s, 1 H, 1-H), 6.1 (bs, 2H, NH2), 3.60 (s, 3H, CH3), 3.56-3.54 (d, 2H, CH2) m/z 281.1515 (M+ + H. C13H19N50 requires m/z 281.1436) Compound 4: 2-benzylhydrazone-6-amino-9-methyl-l-deazapurine Condensation of 2-nitroso-6-amino-9-methyl-l-deazapurine (0.1 g, 0.565 mmol), benzylamine (740 l , 6.77 mmol) and acetic acid CH3COOH (64.6 l, 1.13 mmol) was performed as described for compound 3. Flash chromatography (EA/MeOH/NH4OH 88.5:10:1.5). The product was triturated with cold methanol and dried in vacuo to yield 52.6 mg (35%) of the desired product as a yellow solid. mp:
231.7-232.8 C;
'H NMR (d6-DMSO) b 10.68 (s, 1H, NH), 7.95 (s, 1H, 8-H), 7.77 (s, 1H, CH), 7.64-7.62 (d, 2H, o-Ph), 7.41 (t, 2H, m-Ph), 7.31 (t, 1 H, p-Ph), 6.46 (s, 1 H, 1-H), 6.17 (bs, 2H, NH2) m/z 267.1358 (M+ + H. C13H19N50 requires m/z 267.1280) Compound 5: 2-(4-methoxy-2-benzylhydrazon)-6-amino-9-methyl-1-deazapuri ne Condensation of 2-nitroso-6-amino-9-methyl-l-deazapurine (0.1 g, 0.565 mmol), methoxy-benzylamine (369 l, 2.82 mmol) and acetic acid CH3COOH (64.6 l, 1.13 mmol) was performed as described for compound 3. Flash chromatography (EA/MeOH/NH4OH 94.5:5:0.5). The product was triturated with cold methanol and dried in vacuo to yield 58.5 mg (35%) of the desired product as a yellow solid.
'H NMR (d6-DMSO) b 10.39 (s, 1H, NH), 7.91 (s, 1H, 8-H), 7.75 (s, 1H, CH), 7.56 (d, J 8.53 Hz, 2H, m-Ph), 6.98 (d, J 8.52 Hz, 2H, o-Ph), 6.42 (s, 1 H, 1-H), 6.13 (bs, 2H, NH2), 3.80 (s, 3H, OCH3), 3.64 (s, 3H, CH3) m/z 297.1464. (M+ + H. C13H19N50 requires m/z 297.3271 Compound 6: 2-(2,4-dimethoxy-2-benzylhydrazon)-6-amino-9-methyl-1-deazapurine Condensation of 2-nitroso-6-amino-9-methyl-l-deazapurine (0.075 g, 0.423 mmol), 2,4-dimethoxy-benzylamine (318 l , 2.12 mmol) and acetic acid CH 3COOH (48.4 l, 0.847 mmol) was performed as described for compound 3. Flash chromatography (EA/MeOH/NH4OH 94.5:5:0.5). The product was triturated with cold methanol and ether and dried in vacuo to yield 48.3 mg (35%) of the desired product as a off white solid.
'H NMR (d6-DMSO) b 10.38 (s, 1H, NH), 8.17 (s, 1H, 8-H), 7.78-7.75 (s, 2H, CH
and 1-H), 6.61-6.6 (m, 2H, Ph), 6.40 (s, 1 H, Ph), 6.11 (bs, 2H, NH 2), 3.85 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 3.63 (s, 3H, CH3) m/z 327.1569 (M+ + H. C13H19N50 requires m/z 327.3531 Compound 7: 2-cyclohexylmethylazo-6-amino-9-methyl-l-deazapurine Condensation of 2-nitroso-6-amino-9-methyl-l-deazapurine (0.1 g, 0.565 mmol), cyclohexylmethylamine (367 l , 2.82 mmol) and acetic acid CH3COOH (64.6 l, 1.13 mmol) was performed as described for compound 3. Flash chromatography (EA/MeOH/NH4OH 94.5:5:0.5). The product was triturated with ether and dried in vacuo to yield 72.6 mg (48%) of the desired product as a bright yellow solid.
'H NMR (d6-DMSO) b 9.81 (s, 1 H, NH), 7.71 (1 H, s, 8-H), 7.17 (d J5.31 Hz, 1 H, CH), 6.22 (s, 1 H, 1-H), 6.04 (s, 2H, NH2), 3.6 (s, 3H, CH3), 2.18-2.17 (m, 1 H, cyclohexyl), 1.8-1.76-1.71 (m, 5H, 5x CH) 1.29-1.18 (m, 5H, CH) m/z 273.1828 (M+ + H. C13H19N50 requires m/z 273.1749 Compound 8: 2-(cyclohexylmethyl -hydrazone)-6-amino-9-methyl -1-deaza-puri ne 2-cyclohexylmethylazo-6-amino-9-methyl-l-deazapurine (0.03 g , 0.111 mmol, compound 7) was dissolved in EtOH (5 ml) and a catalytic amount of N(Et)3. The mixture was refluxed overnight. The mixture was concentrated in vacuo, triturated with cold ether and MeOH and fiitered producing 8 mg (27%) of the desired product as a yellow solid.
'H NMR (d6-DMSO) b 9.81 (s, 1H, NH), 7.71 (s, 1H, 8-H), 7.16 (d, J4.91 Hz, 1H, CH), 6.22 (s, 1H, 1-H), 6.04 (s, 2H, NH2), 3.6 (s, 3H, CH3) Table I: Structural variations of compounds 1- 8 N
\
Ri N N
~
(1) R3 Compound R, R2 R3 1 2-oxa-3-azabicyclo[2.2.2]oct-5-en-3-yl NH2 CH3 2 4-hydroxy-cyclohexyl-NH- NH2 CH3 3 Ph-CH2-CH=N-NH- NH2 CH3 4 Ph-CH=N-NH- NH2 CH3 5 4-methoxy-Ph-CH=N-NH- NH2 CH3 6 2,4-dimethoxy-Ph-CH=N-NH- NH2 CH3 7 C clohe I-CH2-N=N- NH2 CH3 8 Cyclohexyl-CH=N-NH- NH2 CH3 EXAMPLE 4: FORMULATION OF COMP. 7 USED IN ANIMAL STUDIES
For oral (p.o.) administration : to the desired quantity (0.5-5 mg) of the solid compound 7 in a glass tube, some glass beads were added and the solid was milled by vortexing for 2 minutes. After addition of 1 ml of a solution of 1%
methylcellulose in water and 2% (v/v) of Poloxamer 188 (Lutrol F68), the compound was suspended by vortexing for 10 minutes. The pH was adjusted to 7 with a few drops of aqueous NaOH (0.1 N). Remaining particles in the suspension were further suspended by using an ultrasonic bath.
For intraperitoneal (i.p.) administration: to the desired quantity (0.5-15 mg) of the solid compound 7 in a glass tube, some glass beads were added and the solid was milled by vortexing for 2 minutes. After addition of 1 ml of a solution of 1%
methylcellulose and 5% mannitol in water, the compound was suspended by vortexing for 10 minutes. Finally the pH was adjusted to 7.
EXAMPLE 5: PHARMACOLOGICAL TESTRESULTS
Adenosine receptor affinity data obtained according to the protocols given above are shown in the table below.
Table II: In vitro adenosine receptor affinity of compounds 1 8 Adenosine receptor aOinity A, Am A3 Compound pK, pK, pK, 1 - - 4.8 2 -- 5.1 3 5.6 5.5 -.-4 5.4 5.9 5.6 5 -- 6.0 6 5.2 5.7 -.-7 6.0 6.1 8 5.5 5.7
EXAMPLE 1: MATERIALS AND METHODS
All reactions involving moisture sensitive compounds were carried out under a dry nitrogen atmosphere. Dichloromethane (phosphorous pentoxide and calciumhydride), tetrahydrofuran (sodium/benzophenone ketyl) and light petroleum (60-80) were distilled freshly prior to use. All other commercially available chemicals were used without further purification. Reactions were monitored by using thi n-layer chromatography (TLC) on silica coated plastic sheets (Merck silica gel 60 F254) with the indicated eluent. The compounds were visualised by UV light (254 nm) or I2.
Flash chromatography refers to purification using the indicated eluent and Acros silica gel (0.030-0.075 mm). Nuclear magnetic resonance spectra (1H NMR and NMR, APT) were determined in the indicated solvent using a Bruker ARX 400 (1H:
400 MHz, 13C: 100 MHz) at 300 K, unless indicated otherwise. 19F NMR and 13C
NMR experiments were carried out on a Varian Inova 500 spectrometer operating at 11.74 T (499.9 MHz for'H; 125.7 MHz for13C; 50.7 Mhz, 470.4 MHz for 19F) using a 5 mm SW probe. The spectra were determined in deuterated chloroform or dichloromethane obtained from Cambridge Isotope Laboratories Ltd. Chemical shifts (b) are given in ppm downfield from tetramethylsilane (1 H, 13C) or CCI3F
(19F).
Coupling constants J are given in Hz. Peakshapes in the NMR spectra are indicated with the symbols 'q' (quartet), 'dq' (double quartet), 't' (triplet), 'dt' (double triplet), 'd' (doublet), 'dd' (double doublet), 's' (singlet), 'bs' (broad singlet) and 'm' (multiplet).
NH and OH signals were identified after mixing the sample with a drop of D 20.
Melting points were measured with a Buchi B-545 Melting Point apparatus. Mass spectra and accurate mass measurements were performed using a JEOL JMS -SX/SX 102 A Tandem Mass Spectrometer using Fast Atom Bombardement (FAB). A
resolving power of 10,000 (10% valley definition) for high resolution FAB mass spectrometry was used. Extinction coefficients were determined with a HP 8453 UV -Vis spectrophotometer. Analytical HPLC was performed on a C18 column (Inertsil ODS-3, particle size 3 mm; 4.6mm 50mm) using the following elution gradient:
linear gradient of 5 % to 95 % aqueous CH3CN containing 0.04 % HCO2H over 5 min, then 95 % aqueous CH3CN containing 0.04 % HCO2H for 2 min at 2.0 ml min"'. Products were detected at k = 254 nm.
EXAMPLE 2: SYNTHESES OF INTERMEDIATES
Intermediate A: 6-Chloro-9-Boc-l-deazapurine To a solution of 6-chloro-1-deazapurine (10 g, 65.1 mmol, J. Heterocyclic Chem.
1982, 19, 513-517) and BOC2O (19.8 g, 91.2 mmol) in dry dichloromethane (100 ml) was added dimethylaminopyridine (0.5 g, 5 mass%) and the mixture was stirred at room temperature for 30 minutes. The reaction was quenched by adding silica and the mixture was filtered over hyflo. Evaporating the solvent yielded the crude product.
Trituration with petroleum ether followed by treatment with ether yielded the product as a white solid (6.29 g, 76%), mp: 183.5 C decomposition 'H NMR (d 6-DMSO) b 8.89 (s, 1 H, H-8), 8.47-8.46 (d, J 5.3 , 1 H, H-2), 7.62-7.61 (1 H, d, J 5.3, H-1), 1.66 ( s, 9H t-Bu).
Intermediate B: 2-nitro-6-chloro-9-Boc-l-deazapurine A solution of 6-chloro-9-Boc-1-deazapurine (1 g, 3.94 mmol, intermediate A) and tetrabutyl-ammoniumnitrate (1.8 g, 5.91 mmol) in dry dichloromethane (12 ml) was stirred in an ice bath. TFAA (835 L, 5.91 mmol) was added dropwise. After 1.5 h the reaction was complete and MeOH (20 ml) was added.The mixture was concentrated and cooled to give yellow crystals. The crude product was washed with 3x3 ml cold MeOH. Drying in vacuo at 50 C afforded the product (0.916 g, 78%) as yellow needles. mp: 288.2-290 C decomposition 'H NMR (d6-DMSO) b 9.22 (s, 1H, H-8), 8.58 (s, 1H, H-1), 1.68 (s, 9H, t-Bu).
Intermediate C: 2-nitro-6-chloro-l-deazapurine 2-nitro-6-chloro-9-Boc-1-deazapurine (1.0 g, 3.35 mmol, intermediate B) in MeOH
(20 ml) was stirred at 70 C. After 2 h the product started to precipitate.
After 15 h the suspension was cooled at 0 C for 30 min and filtered. The precipitate was washed with cold MeOH and dried in vacuo at 50 C to furnish the product (0.5 g, 76%) as a yellow solid. mp: 294.5 C
'H NMR(ds-DMSO) b 14.20 (bs, 1 H, H-9), 8.92 (s, 1 H, H-8), 8.41 (d, 1 H, H-1).
Intermediate D: 6-nitro-9-Boc-l-deazapurine To a solution of 6-nitro-1-deazapurine (5 g, 30 mmol, J.Med.Chem., 1987, 30, 1688) and BOC2O (10 g, 46 mmol) in dry dichloromethane (100 ml) was added dimethylaminopyridine (0.250 g, 5 mass%) and the mixture was stirred at room temperature for 1.5 h. The reaction was diluted with PE and quenc hed by adding silica and the mixture was filtered over hyflo. Evaporating the solvent yielded the crude product. Crystallization with EA/PE afforded the product (2.28 g, 72 %) as light yellow needles. mp: 223-226 C
'H NMR (d6-DMSO) b 9.11 (s, 1 H, H-8), 8.81 (d, J 5.3 , 1 H, H-2), 8.10 (d J
5.3, 1 H, H-1), 1.67 ( s, 9H t-Bu).
Intermediate E: 2,6-dinitro-l-deazapurine A solution of 6-nitro-9-Boc-1-deazapurine (4 g, 15 mmol, intermediate D) and tetrabutylammoniumnitrate (0.92 g, 23 mmol) in dry dichloromethane (5 ml) was stirred at -18 C. TFAA (430 L, 18 mmol) was added dropwise. After 1.5 h the nitration reaction was complete and MeOH (20 ml) was added.The solution was refluxed for 15h while the product precipitates. Cooling and filtering and drying the suspension furnished the pure product (2.28g, 72%) as light yellow crystals.
mp:
'H NMR (d6-DMSO) b 14.45(bs, 1H, H-9), 9.16(s, 1H, H-8), 8.81 (d, 1H, H-1).
Intermediate F: 2-nitro-6-azido-l-deazapurine First possible route: a suspension of 2-nitro-6-chloro-1-deazapurine (12 mmol, intermediate C) and NaN3 (2.5 g, 37 mmol) in dry DMF (25 ml) was stirred and warmed to 60 C. After 60 h the reaction was cooled to room temperature and water was added slowly (100 ml). The product precipitated and was filtered. Washing with water and ether, followed by drying in vacuo at 50 C furnished the product (2.12g, 82%) as a solid.
Alternative route: a suspension of 2,6-dinitro-1-deazapurine (2.5 g, 12 mmol, intermediate E) and NaN3 (2.4 g, 37 mmol) in dry DMF (20 ml) was stirred at room temperature for 3h. After completion, water was added slowly (100 ml). The product precipitated and was filtered. Washing with water and ether, followed by drying in vacuo at 50 C furnished the product (2.22g, 90%) as a off white solid. mp: 220-C decomposition 'H NMR(d6-DMSO) b 14.02 (bs, 1 H, H-9), 8.78 (s, 1 H, H-8), 7.81 (s, 1 H, 1-H).
Intermediate G: 2-nitro-6-azido-9-methyl-l-deazapurine To a suspension of 2-nitro-6-azido-1-deazapurine (6 g, 29.2 mmol, Intermediate F) and K2CO3 (8.09 g, 58.5 mmol) in dry DMF (150 ml) was added Mel (3.65 ml, 58.5 mmol). After 1 h the reaction was complete and water (300 ml) was added slowly.
The product precipitated and the suspension was cooled in an ice -bath. The crude product was washed with water and ether and dried in vacuo at 50 C to yield 5.61g (88%) of the desired product as a white solid. mp: 171.7 C decomposition 'H NMR (d6-DMSO) b 8.77 (s, 1H H-8), 7.80 (s, 1H, H-1), 3.92 (s, 3H, CH3).
Intermediate H: 2-nitro-6-amino-9-Me-l-deazapurine To a solution of 2-nitro-6-azido-9-methyl-1-deazapurine (1 g, 4.5 mmol, Intermediate G) was added Pd/C 10 % (0.200 g, 20 mol%). The solution was stirred at room temperature under a H2 atmosphere. After 1 h the reaction was complete. Flash chromatography (EA) of the crude reaction mixture afforded the pure product as a red solid (0.775 g. 88 %). mp: 260 - 264 C
'H NMR (d6-DMSO) b 8.35 (s, 1H H-8), 7.36 (s, 1H, H-1), 7.15 (bs, 2H, NH2), 3.79 (s, 3H, CH3).
Intermediate I: 2-hydroxylamino-6-amino-9-methyl-l-deazapurine A suspension of 2-nitro-6-azido-9-methyl-1-deazapurine (1 g, 45.6 mmol, Intermediate H) and 10% Pt/C (0.2 g, 20% m) in EA (200 ml) was refluxed under a H2 athmosphere. After 18h the reaction was filtered over Hyflo (EA/MeOH). The filtrate was used immediately for the oxidation reaction to the nitroso derivative.
'H NMR (d6-DMSO) b 8.34 (s, 1H, H-8), 7.36 (s, 1H, H-1), 7.14 (bs, 2H, NH2), 3.80 (s, 3H, CH3).
Intermediate J: 2-nitroso-6-amino-9-methyl-l-deazapurine The crude mixture of 2-hydroxylamino-6-amino-9-methyl-1 -deazapurine (intermediate I) was cooled to 0 C. An ice-cold solution of Na104 (1.95 g, 9.13 mmol) in H20 (50 ml) was added slowly. After 1h the reaction was complete and the organic layer was separated from the water layer. The aqueous layer was extracted with EA + 5%
MeOH and dried with Na2SO4. The yellow solution was concentrated and triturated with cold MeOH to yield 0.53 g (65%) of the desired product as a red solid.
mp:
220 C.
'H NMR (d6-DMSO) b 8.46 (s,1H, H-8), 7.37 (s,1H, H-1), 7.00 (bs, 2H, NH2), 3.92 (s, 3H, CH3) EXAMPLE 3: SYNTHESES OF SPECIFIC COMPOUNDS
Compound 1: 2-(2-oxa-3-azabicyclo[2.2.2]oct-5-en-3-yl)-6,amino-9-methyl-1-deazapuri ne To a suspension of 2-nitroso-6-amino-9-methyl-1-deazapurine (0.1 g, 0.56 mmol, intermediate J) in MeOH (15 ml) was added slowly 1,3-cyclohexadiene (105 l , 1.13 mmol). After 30 m the reaction was complete and the mixture was concentrated and triturated in cold MeOH. The product was washed with cold MeOH and dried at 50 C
in vacuo to yield 101.9 mg (75 %) of the desired product as a white solid. mp:
169.9 C.
'H NMR (d6-DMSO) b 7.82 (s, 1H, H-8), 6.52 (t, 1H, CH), 6.30 (t, 1H, CH) , 6.12 (bs, 2H, NH2), 5.99 (s, 1 H, H-1), 5.21 (t, 1 H, CH), 4.70 (t, 1 H, CH), 3.63 (s, 3H, CH 3), 2.08 (q, 2H, CH2), 1.55 (q, 2H, CH2), 1.33 (q, 2H, CH2);
m/z 258.1355 (M+ + H. C13H16N50 requires m/z 258.1277) Compound 2: 2-(cis-4-hydroxycyclohexylamino)-6-amino-9-methyl-1-deazapurine A suspension of 2-(2-oxa-3-azabicyclo[2.2.2]oct-5-en-3-yl)-6-amino-9-methyl-1-deazapurine (50 mg, 0.194 mmol, compound 1) and 10% Pd/C in MeOH (4 ml) was stirred under 1 atm hydrogen for 1.5 h at 70 C. Filtration, evaporation and stirring in cold MeOH afforded the pure 2-(cis-4-hydroxycyclohexylamino)-6-amino-9-methyl-deazapurine (23,8 mg, 47 %) as white solid.
'H NMR (d6-DMSO) b 7.62 (s, 1H, 8-H), 5.72 (s, 2H, NH2), 5.69-5.67 (m, 1H, NH), 5.57 (s, 1 h, 1-H), 4.34 (s, 1 H, OH), 3.69 (s, 2H), 3.57 (s, 3H, CH 3), 1.63 (m, 6H, cyclo), 1.53-151 (m, 2H, cyclo) m/z 262.1668 (M+ + H. C13H19N50 requires m/z 262.1590) Compound 3:2-(2-phenylethyl-hydrazone)-6-amino-9-methyl-1-deazapurine A mixture of 2-nitroso-6-amino-9-methyl-1-deazapurine (0.1 g, 0.565 mmol), 2-phenylethylamine (858 l, 0.677 mmol) and acetic acid CH3COOH (64.6 l, 1.13 mmol) was stirred in MeOH. After 3 h the suspension had dissolved. The yellow solution was concentrated and diluted with PE and purified by flash chromatography (EA/MeOH/NH4OH 88.5:10:1.5). The product was triturated with cold methanol and dried in vacuo to yield 55.4 mg (35%) of the desired product as a yellow solid. mp:
182.1 C
'H NMR (d6-DMSO) b 10.07 (s, 1H, NH), 7.73 (s, 1H, 8-H), 7.37-7.32 (3H, m, CH/Ph), 7.27-7.25-7.23 (m, 3H, Ph), 6.28 (s, 1 H, 1-H), 6.1 (bs, 2H, NH2), 3.60 (s, 3H, CH3), 3.56-3.54 (d, 2H, CH2) m/z 281.1515 (M+ + H. C13H19N50 requires m/z 281.1436) Compound 4: 2-benzylhydrazone-6-amino-9-methyl-l-deazapurine Condensation of 2-nitroso-6-amino-9-methyl-l-deazapurine (0.1 g, 0.565 mmol), benzylamine (740 l , 6.77 mmol) and acetic acid CH3COOH (64.6 l, 1.13 mmol) was performed as described for compound 3. Flash chromatography (EA/MeOH/NH4OH 88.5:10:1.5). The product was triturated with cold methanol and dried in vacuo to yield 52.6 mg (35%) of the desired product as a yellow solid. mp:
231.7-232.8 C;
'H NMR (d6-DMSO) b 10.68 (s, 1H, NH), 7.95 (s, 1H, 8-H), 7.77 (s, 1H, CH), 7.64-7.62 (d, 2H, o-Ph), 7.41 (t, 2H, m-Ph), 7.31 (t, 1 H, p-Ph), 6.46 (s, 1 H, 1-H), 6.17 (bs, 2H, NH2) m/z 267.1358 (M+ + H. C13H19N50 requires m/z 267.1280) Compound 5: 2-(4-methoxy-2-benzylhydrazon)-6-amino-9-methyl-1-deazapuri ne Condensation of 2-nitroso-6-amino-9-methyl-l-deazapurine (0.1 g, 0.565 mmol), methoxy-benzylamine (369 l, 2.82 mmol) and acetic acid CH3COOH (64.6 l, 1.13 mmol) was performed as described for compound 3. Flash chromatography (EA/MeOH/NH4OH 94.5:5:0.5). The product was triturated with cold methanol and dried in vacuo to yield 58.5 mg (35%) of the desired product as a yellow solid.
'H NMR (d6-DMSO) b 10.39 (s, 1H, NH), 7.91 (s, 1H, 8-H), 7.75 (s, 1H, CH), 7.56 (d, J 8.53 Hz, 2H, m-Ph), 6.98 (d, J 8.52 Hz, 2H, o-Ph), 6.42 (s, 1 H, 1-H), 6.13 (bs, 2H, NH2), 3.80 (s, 3H, OCH3), 3.64 (s, 3H, CH3) m/z 297.1464. (M+ + H. C13H19N50 requires m/z 297.3271 Compound 6: 2-(2,4-dimethoxy-2-benzylhydrazon)-6-amino-9-methyl-1-deazapurine Condensation of 2-nitroso-6-amino-9-methyl-l-deazapurine (0.075 g, 0.423 mmol), 2,4-dimethoxy-benzylamine (318 l , 2.12 mmol) and acetic acid CH 3COOH (48.4 l, 0.847 mmol) was performed as described for compound 3. Flash chromatography (EA/MeOH/NH4OH 94.5:5:0.5). The product was triturated with cold methanol and ether and dried in vacuo to yield 48.3 mg (35%) of the desired product as a off white solid.
'H NMR (d6-DMSO) b 10.38 (s, 1H, NH), 8.17 (s, 1H, 8-H), 7.78-7.75 (s, 2H, CH
and 1-H), 6.61-6.6 (m, 2H, Ph), 6.40 (s, 1 H, Ph), 6.11 (bs, 2H, NH 2), 3.85 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 3.63 (s, 3H, CH3) m/z 327.1569 (M+ + H. C13H19N50 requires m/z 327.3531 Compound 7: 2-cyclohexylmethylazo-6-amino-9-methyl-l-deazapurine Condensation of 2-nitroso-6-amino-9-methyl-l-deazapurine (0.1 g, 0.565 mmol), cyclohexylmethylamine (367 l , 2.82 mmol) and acetic acid CH3COOH (64.6 l, 1.13 mmol) was performed as described for compound 3. Flash chromatography (EA/MeOH/NH4OH 94.5:5:0.5). The product was triturated with ether and dried in vacuo to yield 72.6 mg (48%) of the desired product as a bright yellow solid.
'H NMR (d6-DMSO) b 9.81 (s, 1 H, NH), 7.71 (1 H, s, 8-H), 7.17 (d J5.31 Hz, 1 H, CH), 6.22 (s, 1 H, 1-H), 6.04 (s, 2H, NH2), 3.6 (s, 3H, CH3), 2.18-2.17 (m, 1 H, cyclohexyl), 1.8-1.76-1.71 (m, 5H, 5x CH) 1.29-1.18 (m, 5H, CH) m/z 273.1828 (M+ + H. C13H19N50 requires m/z 273.1749 Compound 8: 2-(cyclohexylmethyl -hydrazone)-6-amino-9-methyl -1-deaza-puri ne 2-cyclohexylmethylazo-6-amino-9-methyl-l-deazapurine (0.03 g , 0.111 mmol, compound 7) was dissolved in EtOH (5 ml) and a catalytic amount of N(Et)3. The mixture was refluxed overnight. The mixture was concentrated in vacuo, triturated with cold ether and MeOH and fiitered producing 8 mg (27%) of the desired product as a yellow solid.
'H NMR (d6-DMSO) b 9.81 (s, 1H, NH), 7.71 (s, 1H, 8-H), 7.16 (d, J4.91 Hz, 1H, CH), 6.22 (s, 1H, 1-H), 6.04 (s, 2H, NH2), 3.6 (s, 3H, CH3) Table I: Structural variations of compounds 1- 8 N
\
Ri N N
~
(1) R3 Compound R, R2 R3 1 2-oxa-3-azabicyclo[2.2.2]oct-5-en-3-yl NH2 CH3 2 4-hydroxy-cyclohexyl-NH- NH2 CH3 3 Ph-CH2-CH=N-NH- NH2 CH3 4 Ph-CH=N-NH- NH2 CH3 5 4-methoxy-Ph-CH=N-NH- NH2 CH3 6 2,4-dimethoxy-Ph-CH=N-NH- NH2 CH3 7 C clohe I-CH2-N=N- NH2 CH3 8 Cyclohexyl-CH=N-NH- NH2 CH3 EXAMPLE 4: FORMULATION OF COMP. 7 USED IN ANIMAL STUDIES
For oral (p.o.) administration : to the desired quantity (0.5-5 mg) of the solid compound 7 in a glass tube, some glass beads were added and the solid was milled by vortexing for 2 minutes. After addition of 1 ml of a solution of 1%
methylcellulose in water and 2% (v/v) of Poloxamer 188 (Lutrol F68), the compound was suspended by vortexing for 10 minutes. The pH was adjusted to 7 with a few drops of aqueous NaOH (0.1 N). Remaining particles in the suspension were further suspended by using an ultrasonic bath.
For intraperitoneal (i.p.) administration: to the desired quantity (0.5-15 mg) of the solid compound 7 in a glass tube, some glass beads were added and the solid was milled by vortexing for 2 minutes. After addition of 1 ml of a solution of 1%
methylcellulose and 5% mannitol in water, the compound was suspended by vortexing for 10 minutes. Finally the pH was adjusted to 7.
EXAMPLE 5: PHARMACOLOGICAL TESTRESULTS
Adenosine receptor affinity data obtained according to the protocols given above are shown in the table below.
Table II: In vitro adenosine receptor affinity of compounds 1 8 Adenosine receptor aOinity A, Am A3 Compound pK, pK, pK, 1 - - 4.8 2 -- 5.1 3 5.6 5.5 -.-4 5.4 5.9 5.6 5 -- 6.0 6 5.2 5.7 -.-7 6.0 6.1 8 5.5 5.7
Claims (7)
1. Compounds of the general formula (1):
wherein:
- R1 represents 2-oxa-3-azabicyclo[2.2.2]oct-5-en-3-yl, 4-hydroxy-cyclohexyl-NH-, optionally substituted arylalkyl(C1-3)amines, cycloalkyl (C3-8)alkyl-(C1-3)amines, arylalkyl(C1-3) hydrazines or cycloalkyl(C3-8)alkyl (C1-3)hydrazines - R2 represents amino, NH-alkyl(C1-3) or N-dialkyl(C1-3) optionally substituted arylalkyl(C1-3)amines or cycloalkyl(C3-8)alkyl-(C1-3)amines, - R3 represents hydrogen, alkyl(C1-3) or arylalkyl(C1-3) and tautomers, stereoisomers and salts thereof
wherein:
- R1 represents 2-oxa-3-azabicyclo[2.2.2]oct-5-en-3-yl, 4-hydroxy-cyclohexyl-NH-, optionally substituted arylalkyl(C1-3)amines, cycloalkyl (C3-8)alkyl-(C1-3)amines, arylalkyl(C1-3) hydrazines or cycloalkyl(C3-8)alkyl (C1-3)hydrazines - R2 represents amino, NH-alkyl(C1-3) or N-dialkyl(C1-3) optionally substituted arylalkyl(C1-3)amines or cycloalkyl(C3-8)alkyl-(C1-3)amines, - R3 represents hydrogen, alkyl(C1-3) or arylalkyl(C1-3) and tautomers, stereoisomers and salts thereof
2. Compounds as claimed in claim 1 of general formula (1) in which - R1 represents oxa-3-azabicyclo[2.2.2]oct-5-en-3-yl, 4-hydroxy-cyclohexyl-NH-, Ph-CH2-CH=N-NH-, Ph-CH=N-NH-, 4-methoxy-Ph-CH=N-NH-, 2,4-dimethoxy-Ph-CH=N-NH-, cyclohexyl-CH2-N=N- or cyclohexyl-CH=N-NH-, - R2 represents amino - R3 represents methyl and tautomers, stereoisomers and salts thereof.
3. The compound according to claim 1 which is:
2-(2-oxa-3-azabicyclo[2.2.2]oct-5-en-3-yl)-6-amino-9-methyl-1-deazapurine 2-(cis-4-hydroxycyclohexylamino)-6-amino-9-methyl-1-deazapurine 2-(2-phenylethyl-hydrazone)-6-amino-9-methyl-1-deazapurine 2-benzylhydrazone-6-amino-9-methyl-1-deazapurine 2-(4-methoxy-2-benzylhydrazon)-6-amino-9-methyl-1-deazapurine 2-(2,4-dimethoxy-2-benzylhydrazon)-6-amino-9-methyl-1-deazapurine 2-cyclohexylmethylazo-6-amino-9-methyl-1-deazapurine 2-(cyclohexylmethyl-hydrazone)-6-amino-9-methyl-1-deaza-purine
2-(2-oxa-3-azabicyclo[2.2.2]oct-5-en-3-yl)-6-amino-9-methyl-1-deazapurine 2-(cis-4-hydroxycyclohexylamino)-6-amino-9-methyl-1-deazapurine 2-(2-phenylethyl-hydrazone)-6-amino-9-methyl-1-deazapurine 2-benzylhydrazone-6-amino-9-methyl-1-deazapurine 2-(4-methoxy-2-benzylhydrazon)-6-amino-9-methyl-1-deazapurine 2-(2,4-dimethoxy-2-benzylhydrazon)-6-amino-9-methyl-1-deazapurine 2-cyclohexylmethylazo-6-amino-9-methyl-1-deazapurine 2-(cyclohexylmethyl-hydrazone)-6-amino-9-methyl-1-deaza-purine
4. A pharmaceutical composition comprising, in addition to a pharmaceutically acceptable carrier and/or at least one pharmaceutically acceptable auxiliary substance, a pharmacologically active amount of at least one compound of one of the claims 1-3, or a salt thereof, as an active ingredient.
5.A method of preparing pharmaceutical compositions as claimed in claim 4, characterized in that a compound of one of the claims 1 -3 is brought into a form suitable for administration.
6. A compound as claimed in any of the claims 1-3, or a salt thereof, for use as a medicament
7. Use of a compound as claimed in any of the claims 1-2 for the preparation of a pharmaceutical composition for the treatment of acute and chronic pain, inflammatory diseases including, arthritis, multiple sclerosis, asthma and psoriasis; gastro-intestinal disorders such as ulcers, inflammatory bowel disease and ulcerative colitis; allergic responses such as eczema, atopic dermatitis and rhinitis; cardio-vascular disorders such as myocardial infarction, arrhythmias, hypertension, thrombosis, anaemia, arteriosclerosis, angina pectoris, cutaneous diseases such as urticaria, lupus erythematosus and pruritus; opthalmological disorders like glaucoma; respiratory disorders including chronic obstructive pulmonary disease, bronchitis and cystic fibrosis; central nervous system disorders including various forms of epilepsy, stroke, depression, sleep apnoea;
disorders characterized by impairment of cognition and memory such as Alzheimer's disease, Creutzfeldt-Jacob disease, Huntington's disease, Parkinson's disease, neurorehabilitation (post-traumatic brain lesions); acute brain or spinal cord injury; diabetes, osteoporosis, diseases of the immune system, various carcinomas and leukemia, bacterial and viral infections.
disorders characterized by impairment of cognition and memory such as Alzheimer's disease, Creutzfeldt-Jacob disease, Huntington's disease, Parkinson's disease, neurorehabilitation (post-traumatic brain lesions); acute brain or spinal cord injury; diabetes, osteoporosis, diseases of the immune system, various carcinomas and leukemia, bacterial and viral infections.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60814504P | 2004-09-09 | 2004-09-09 | |
US60/608,145 | 2004-09-09 | ||
EP04104345 | 2004-09-09 | ||
EP04104345.6 | 2004-09-09 | ||
PCT/EP2005/054405 WO2006027366A1 (en) | 2004-09-09 | 2005-09-07 | 2-substituted-1-deaza purine derivatives with adenosine receptor modulating activity |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2579303A1 true CA2579303A1 (en) | 2006-03-16 |
Family
ID=34929558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002579303A Abandoned CA2579303A1 (en) | 2004-09-09 | 2005-09-07 | 2-substituted-1-deaza purine derivatives with adenosine receptor modulating activity |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1791841A1 (en) |
AR (1) | AR050860A1 (en) |
CA (1) | CA2579303A1 (en) |
TW (1) | TW200616624A (en) |
WO (1) | WO2006027366A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7338964B2 (en) | 2004-09-09 | 2008-03-04 | Solvay Pharmaceuticals, B.V. | 2-substituted-1-deaza purine derivatives with adenosine receptor modulating activity |
US7371737B2 (en) | 2004-09-09 | 2008-05-13 | Solvay Pharmaceuticals, B.V. | 2-substituted-6-trifluoromethyl purine derivatives with adenosine-A3 antagonistic activity |
US7462534B2 (en) | 2005-08-02 | 2008-12-09 | Micron Technology, Inc. | Methods of forming memory circuitry |
US20080146536A1 (en) * | 2005-08-16 | 2008-06-19 | Pharmacopeia, Inc. | 2-Aminoimidazopyridines for treating neurodegenerative diseases |
WO2009034411A1 (en) * | 2007-09-12 | 2009-03-19 | Centre National De La Recherche Scientifique | Perharidines as cdk inhibitors |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3820989A (en) * | 1988-08-02 | 1990-02-08 | Ciba-Geigy Ag | 7-amino-3-beta-d-ribofuranosyl-3h-imidazo(4,5-b) pyridin-5-amine derivatives |
-
2005
- 2005-09-02 TW TW094130124A patent/TW200616624A/en unknown
- 2005-09-06 AR ARP050103719A patent/AR050860A1/en not_active Application Discontinuation
- 2005-09-07 EP EP05789581A patent/EP1791841A1/en not_active Ceased
- 2005-09-07 CA CA002579303A patent/CA2579303A1/en not_active Abandoned
- 2005-09-07 WO PCT/EP2005/054405 patent/WO2006027366A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
AR050860A1 (en) | 2006-11-29 |
EP1791841A1 (en) | 2007-06-06 |
WO2006027366A1 (en) | 2006-03-16 |
TW200616624A (en) | 2006-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3572412B1 (en) | Pyridine derivative as ask1 inhibitor and preparation method and use thereof | |
EP3684767B1 (en) | Heterocyclic compounds as pad inhibitors | |
KR102081272B1 (en) | Janus kinase inhibitor | |
US7132439B2 (en) | Bis-benzimidazoles and related compounds as potassium channel modulators | |
WO2019141250A1 (en) | Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor | |
EP3572401A1 (en) | Ask1 inhibitor and preparation method and use thereof | |
EP1866286B1 (en) | Pyridine derivatives useful as inhibitors of pkc-theta | |
FR2852957A1 (en) | NOVEL IMIDAZO-PYRIDINE DERIVATIVES AND THEIR USE AS A MEDICINAL PRODUCT | |
WO2005080330A1 (en) | Heteroarylphenylurea derivative | |
CA2680775A1 (en) | Aza-pyridopyrimidinone derivatives | |
JP7425724B2 (en) | Amine-substituted heterocyclic compounds and derivatives thereof as EHMT2 inhibitors | |
US7371737B2 (en) | 2-substituted-6-trifluoromethyl purine derivatives with adenosine-A3 antagonistic activity | |
SG192446A1 (en) | Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives | |
JP2021523875A (en) | Pyrazine-2 (1H) -one compound as an FGFR inhibitor | |
CA2579303A1 (en) | 2-substituted-1-deaza purine derivatives with adenosine receptor modulating activity | |
JPH0655728B2 (en) | Histamine derivative, method for producing the same, and medicament containing the derivative | |
CN114524810B (en) | Pyrimidine heterocyclic compounds, preparation method and application | |
EP3299371B1 (en) | Hydroxyl purine compounds and use thereof | |
TWI706950B (en) | Diaza-benzofluoranthene compound | |
EP0237467A2 (en) | Heteroaryl-oxy-beta-carboline derivatives, their preparation and use as medicaments | |
CN116348468A (en) | CFTR modulator compounds, compositions and uses thereof | |
EP2185558B1 (en) | Tricyclic n-heteroaryl-carboxamide derivatives, preparation thereof and therapeutic use of same | |
CA2579302A1 (en) | 2-substituted-6-trifluoromethyl purine derivatives with adenosine-a3 antagonistic activity | |
US7338964B2 (en) | 2-substituted-1-deaza purine derivatives with adenosine receptor modulating activity | |
CN111606888B (en) | Pyrrole derivative and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |